Embecta (EMBC) reported fiscal Q1 adjusted earnings Thursday of $0.65 per diluted share, up from $0.61 a year earlier.
Analysts polled by FactSet expected $0.44.
Revenue for the quarter ended Dec. 31 was $261.9 million, down from $277.3 million a year earlier.
Analysts surveyed by FactSet expected $254.6 million.
The medical device company said it continues to expect 2025 adjusted EPS of $2.70 to $2.90. Analysts polled by FactSet expect $2.80.
Revenue for the fiscal year is now expected to be $1.08 billion to $1.09 billion, compared with prior guidance of between $1.09 billion and $1.11 billion. Analysts surveyed by FactSet expect $1.10 billion.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。